📷 Image: Wikimedia Commons / Kristoferb (talk)
Business
Cipla's Pune unit licence revoked over alleged irregularities
✍️ NDTV
🗓 29 Aug 2026, 11:03 AM
👁 1
The drug sale licence of Cipla's manufacturing unit in Pune has been cancelled by authorities citing irregularities in its operations.
The Maharashtra State Drug Control Department has withdrawn the drug sale licence of Cipla's Pune manufacturing unit, alleging procedural irregularities. The decision, announced on Monday, follows a routine inspection that reportedly uncovered deviations from the norms governing pharmaceutical sales and distribution.
Cipla, a major Indian pharmaceutical company, has not yet released an official comment on the revocation. Industry analysts suggest that the move could temporarily affect the supply of certain generic medicines produced at the Pune plant, though the impact on nationwide distribution remains unclear.
The department has indicated that Cipla will be given an opportunity to address the concerns and may apply for reinstatement after complying with the required corrective measures. The revocation underscores the regulator's heightened scrutiny of drug manufacturing practices across the country.
Stakeholders, including healthcare providers and patients, are advised to monitor updates from both the company and the regulatory authority for any changes in product availability.
Cipla, a major Indian pharmaceutical company, has not yet released an official comment on the revocation. Industry analysts suggest that the move could temporarily affect the supply of certain generic medicines produced at the Pune plant, though the impact on nationwide distribution remains unclear.
The department has indicated that Cipla will be given an opportunity to address the concerns and may apply for reinstatement after complying with the required corrective measures. The revocation underscores the regulator's heightened scrutiny of drug manufacturing practices across the country.
Stakeholders, including healthcare providers and patients, are advised to monitor updates from both the company and the regulatory authority for any changes in product availability.